How strong were Emerson's orders, and why do they matter?

Underlying orders grew 9% in the quarter, the fourth straight quarter of strong growth. Orders are a leading indicator of future sales, so this momentum, concentrated in Software & Systems, suggests revenue growth could accelerate in coming quarters. Underlying orders exclude AspenTech.

Did Emerson's profitability improve or deteriorate?

Adjusted EPS grew 6% to $1.46, but margins contracted. Adjusted segment EBITA margin fell 30 bps to 27.7%, and GAAP pretax margin fell 80 bps to 17.8%, largely because interest expense rose sharply to $90 million from $8 million. Management characterized profitability as ahead of expectations.

Why did cash flow decline, and is it a concern?

Operating cash flow fell 10% to $699 million and free cash flow fell 13% to $602 million, mainly due to a $357 million working capital outflow versus $154 million a year earlier. Management still guides to $3.5–$3.6 billion of full-year free cash flow, so investors will watch whether working capital normalizes in the remaining quarters.

How is Emerson funding its share buybacks and debt?

Total debt rose to roughly $13.4 billion, with short-term borrowings and current maturities at $5.8 billion, up from $4.8 billion in September. The company issued $3.5 billion in short-term borrowings during the quarter and repaid $2.1 billion, plus $587 million of long-term debt. Share repurchases were $250 million in Q1 and are guided to about $1.0 billion for the full year, so investors may question how the balance sheet supports the planned $2.2 billion of shareholder returns.

What is the outlook for the rest of fiscal 2026?

Management guides to adjusted EPS of $6.40–$6.55 for FY2026 and $1.50–$1.55 for Q2, with Q2 underlying sales growth of 1–2%. Full-year net sales growth is expected at about 5.5% (about 4% underlying), with operating cash flow of $4.0–$4.1 billion. The guidance implies a slowdown in underlying sales growth in Q2 before a potential acceleration, which will be a key focus for investors.

EMR 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 3, 2026. Cited figures are marked; the original filing is the authoritative source.

Emerson Electric (EMR) reported first quarter fiscal 2026 results (quarter ended December 31, 2025) that were broadly in line on sales and ahead of expectations on profitability, while updating its full-year fiscal 2026 outlook.

Net sales rose 4% to $4,346 million^a, with underlying sales growth of 2% after currency and acquisition/divestiture effects. Underlying orders grew 9%, marking a fourth consecutive quarter of strong underlying orders growth, led by the Software & Systems segment (Test & Measurement grew 14% reported). GAAP EPS rose 5% to $1.07 and adjusted EPS rose 6% to $1.46.

Margins compressed: GAAP pretax margin fell 80 bps to 17.8%, and adjusted segment EBITA margin fell 30 bps to 27.7%, with higher interest expense ($90 million^b vs. $8 million) following the company's debt activity. Cash generation weakened in the quarter. Operating cash flow declined 10% to $699 million and free cash flow fell 13% to $602 million, driven by higher working capital investment.

Total debt rose to about $13.4 billion^c, with short-term borrowings and current maturities of $5.8 billion, up from $4.8 billion at September 30, 2025. Management pivoted capital allocation toward shareholder returns, with a 2026 outlook assuming about $2.2 billion returned: roughly $1.0 billion in share repurchases and $1.2 billion in dividends. Q1 share repurchases were $250 million, versus $899 million a year earlier.

Full-year fiscal 2026 guidance calls for net sales growth of about 5.5% (underlying growth of about 4%), adjusted EPS of $6.40 to $6.55^d, operating cash flow of $4.0 to $4.1 billion, and free cash flow of $3.5 to $3.6 billion. Q2 guidance calls for adjusted EPS of $1.50 to $1.55 and underlying sales growth of 1% to 2%. Investors will likely focus on whether the strong orders momentum converts into sales acceleration in the back half, whether margins recover, and how the elevated debt load and buyback program are financed.

02—Key points

Key Highlights

Net sales rose 4% to $4,346 million; underlying sales grew 2%, with Test & Measurement up 11% underlying and Software & Systems up 3%.
Underlying orders grew 9%, the fourth consecutive quarter of strong orders growth, led by Software & Systems with strength in North America, India, and Middle East & Africa.
Adjusted EPS rose 6% to $1.46 and GAAP EPS rose 5% to $1.07, with management stating it exceeded profitability expectations.
Adjusted segment EBITA margin declined 30 bps to 27.7%, and GAAP pretax margin declined 80 bps to 17.8%, as interest expense rose to $90 million from $8 million.
Operating cash flow fell 10% to $699 million and free cash flow fell 13% to $602 million, driven by a $357 million working capital outflow.
FY2026 guidance: adjusted EPS of $6.40–$6.55, net sales growth of about 5.5%, underlying growth of about 4%, and free cash flow of $3.5–$3.6 billion.
Capital allocation pivot: about $2.2 billion planned for shareholder returns in FY2026 (about $1.0 billion buybacks and $1.2 billion dividends); quarterly dividend declared at $0.555 per share.

03—Questions

Frequently Asked Questions

How strong were Emerson's orders, and why do they matter?
Underlying orders grew 9% in the quarter, the fourth straight quarter of strong growth. Orders are a leading indicator of future sales, so this momentum, concentrated in Software & Systems, suggests revenue growth could accelerate in coming quarters. Underlying orders exclude AspenTech.
Did Emerson's profitability improve or deteriorate?
Adjusted EPS grew 6% to $1.46, but margins contracted. Adjusted segment EBITA margin fell 30 bps to 27.7%, and GAAP pretax margin fell 80 bps to 17.8%, largely because interest expense rose sharply to $90 million from $8 million. Management characterized profitability as ahead of expectations.
Why did cash flow decline, and is it a concern?
Operating cash flow fell 10% to $699 million and free cash flow fell 13% to $602 million, mainly due to a $357 million working capital outflow versus $154 million a year earlier. Management still guides to $3.5–$3.6 billion of full-year free cash flow, so investors will watch whether working capital normalizes in the remaining quarters.
How is Emerson funding its share buybacks and debt?
Total debt rose to roughly $13.4 billion, with short-term borrowings and current maturities at $5.8 billion, up from $4.8 billion in September. The company issued $3.5 billion in short-term borrowings during the quarter and repaid $2.1 billion, plus $587 million of long-term debt. Share repurchases were $250 million in Q1 and are guided to about $1.0 billion for the full year, so investors may question how the balance sheet supports the planned $2.2 billion of shareholder returns.
What is the outlook for the rest of fiscal 2026?
Management guides to adjusted EPS of $6.40–$6.55 for FY2026 and $1.50–$1.55 for Q2, with Q2 underlying sales growth of 1–2%. Full-year net sales growth is expected at about 5.5% (about 4% underlying), with operating cash flow of $4.0–$4.1 billion. The guidance implies a slowdown in underlying sales growth in Q2 before a potential acceleration, which will be a key focus for investors.

04—Continue

← View all 8-K filings